Mumbai & Tokyo, September 20, 2016: Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced the initiation of a phased transfer of manufacturing & marketing rights in Japan for the 14 long-listed/established prescription brands acquired from Novartis. These 14 prescription brands acquired by the company earlier this year will be transferred from Novartis Pharma K.K. to Sun Pharma’s subsidiary in Japan beginning October 2016.
Sun Pharma has also signed a strategic distribution alliance with Mitsubishi Tanabe Pharma Corporation for these 14 prescription brands. Under this alliance, following the transfer of manufacturing & marketing rights to Sun Pharma’s subsidiary in Japan, Mitsubishi Tanabe Pharma Corporation will market and distribute all the 14 brands as well as provide information on their proper use to healthcare professionals.
According to Isao Muramatsu, President & Representative Director, Sun Pharma Japan Ltd, Sun Pharma, “Through this alliance we have the opportunity to leverage Mitsubishi Tanabe Pharma Corporation’s specialized expertise to create a strong business foundation for us in Japan. Sun Pharma will focus on expanding its sales channels in Japan’s pharmaceutical market while continuing to ensure a stable supply of medicines and healthcare information.”
The schedule of transfer of these 14 brands is given below:
Date of Transfer: October 20, 2016
|
Brand name |
Generic name |
Major indications |
Scheduled date of sale |
|
Parlodel® |
Bromocriptine mesylate |
Parkinson’s syndrome |
November 1, 2016 |
|
Lamisil® |
Terbinafine |
Tinea unguium, tinea manuum and pedis, candidiasis |
|
|
Nitroderm® |
Nitroglycerin |
Angina pectoris |
November 21, 2016 |
Date of Transfer: November 21, 2016
|
Brand name |
Generic name |
Major indications |
Scheduled date of sale |
|
Apresoline® |
Hydralazine hydrochloride |
Essential hypertension |
December 1, 2016 |
|
Zaditen® |
Ketotifen fumarate |
Allergic rhinitis |
|
|
Symmetrel® |
Amantadine hydrochloride |
Parkinson’s syndrome |
|
|
Cibacen® |
Benazepril hydrochloride |
Hypertension |
|
|
Tegretol® |
Carbamazepine |
Epilepsy |
|
Pursennid® |
Sennosides A and B |
Constipation |
|
|
Lioresal® |
Baclofen |
Spastic paralysis associated with cerebrovascular disorder |
|
|
Lopresor® |
Metoprolol tartrate |
Angina pectoris, achyarrhythmia |
Scheduled transfers in 2017
|
Brand name |
Generic name |
Major indications |
Scheduled date of sale |
|
Ternelin™ |
Tizanidine hydrochloride |
Neck, lumbago Shoulder and arm Syndrome |
2017 |
|
Ludiomil® |
Maprotiline hydrochloride |
Depression |
|
|
Lochol® |
Fluvastatin sodium |
Hypercholesterolemia |
Corporate Comm India (CCI Newswire)
